Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $10.27 down -7.64% from its previous closing price of $11.12. In other words, the price has decreased by -$7.64 from its previous closing price. On the day, 4.87 million shares were traded. OCUL stock price reached its highest trading level at $11.0675 during the session, while it also had its lowest trading level at $10.18.
Ratios:
For a deeper understanding of Ocular Therapeutix Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.78 and its Current Ratio is at 7.85. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.29.
Upgrades & Downgrades
In the most recent recommendation for this company, Chardan Capital Markets on September 15, 2025, initiated with a Buy rating and assigned the stock a target price of $21.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.RBC Capital Mkts initiated its Outperform rating on March 18, 2025, with a $17 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 24 ’25 when Nayak Sanjay sold 1,878 shares for $12.04 per share. The transaction valued at 22,611 led to the insider holds 277,860 shares of the business.
Dugel Pravin sold 19,530 shares of OCUL for $235,141 on Nov 24 ’25. The insider now owns 3,157,960 shares after completing the transaction at $12.04 per share. On Nov 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,007 shares for $12.02 each. As a result, the insider received 36,144 and left with 191,433 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 2187997696 and an Enterprise Value of 1920233600. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.23 while its Price-to-Book (P/B) ratio in mrq is 6.96. Its current Enterprise Value per Revenue stands at 34.423 whereas that against EBITDA is -7.388.
Stock Price History:
The Beta on a monthly basis for OCUL is 0.91, which has changed by 0.30164766 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $16.44, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is -16.20%, while the 200-Day Moving Average is calculated to be -5.00%.
Shares Statistics:
For the past three months, OCUL has traded an average of 3.58M shares per day and 6997100 over the past ten days. A total of 213.05M shares are outstanding, with a floating share count of 186.31M. Insiders hold about 12.55% of the company’s shares, while institutions hold 79.26% stake in the company. Shares short for OCUL as of 1767139200 were 12345939 with a Short Ratio of 3.44, compared to 1764288000 on 11633800. Therefore, it implies a Short% of Shares Outstanding of 12345939 and a Short% of Float of 5.81.
Earnings Estimates
Ocular Therapeutix Inc (OCUL) is presently subject to a detailed evaluation by 3.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.32 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$1.34 and -$1.49 for the fiscal current year, implying an average EPS of -$1.43. EPS for the following year is -$1.48, with 3.0 analysts recommending between -$1.3 and -$1.58.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $16.14M this quarter.It ranges from a high estimate of $28.4M to a low estimate of $11.6M. The current estimate, Ocular Therapeutix Inc’s year-ago sales were $17.08MFor the next quarter, 12 analysts are estimating revenue of $14.01M. There is a high estimate of $16.6M for the next quarter, whereas the lowest estimate is $11.5M.
A total of 12 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $67.1M, while the lowest revenue estimate was $50.3M, resulting in an average revenue estimate of $54.83M. In the same quarter a year ago, actual revenue was $63.72MBased on 12 analysts’ estimates, the company’s revenue will be $66.04M in the next fiscal year. The high estimate is $115.2M and the low estimate is $52.3M.
